Eloïse Thomas is an Associate Professor at the University of Lyon (France). She teaches at the Faculty of Pharmacy on subjects related to galenic pharmacy and physico-chemistry of active pharmaceutical ingredients and dosage forms. In parallel, she carries out research projects at the LAGEPP (Laboratory of Automatic Control, Chemical and Pharmaceutical Engineering) UMR-CNRS 5007. Her work stands at the interface of physico-chemistry and biology and focuses on the development of new systems for health applications.
In 2017, she obtained her PhD at the University of Lyon (France) where her research focused on an ultrasmall nanoparticle (AGuIX®) for the diagnosis and treatment of cancers. By modifying the particle surface, she developed a second generation of particles for MRI-guided PDT, SPECT and PET imaging, radiosensitisation or tumor active targeting.
She continued her research at the University of Oxford (United-Kingdom) as a postdoctoral researcher where she investigated the use of ultrasound to improve the delivery of radiopharmaceuticals and chemotherapeutic drugs to tumours.
In 2019, she was appointed Associate Professor at the University of Lyon (France). She is currently working on the development of nanovectors for therapeutic purposes in oncology, their characterization and the biological evaluation of their properties. SPECT and PET imaging are used to assess the biodistribution of therapeutic agents and their vectors. In parallel, Eloïse is also working on the use of metallic oxide nanoparticles and their formulations for skin decontamination of chemical toxins.